Genentech Inc, the amalgamation of Genetic Engineering Technology Inc is the foremost biotechnology enterprise which was established by the entrepreneur industrialist Robert A. Swanson in association with Dr. Herbert W. Boyer, during 1976, with the company’s headquarters situated at Southern San Francisco, California in the United States of America. One of the founders Dr. Boyer is believed to be amongst the pioneers in the sector of Recombinant DNA technology.

 

During 1973 Dr. Boyer in association with his colleague Stanley Norman Cohen, the Recombinant inherent engineering after understanding that restraint enzymes could be used as scissors for curtailing DNA fragments of interest from one source, to be ligated into the same cut plasmid vector. The company aims to be the foremost biotechnology enterprise using human genetic information for discovering, developing, producing and marketing bio-therapeutics that may help meeting vital challenging medical necessities.

 

Genentech is dedicated to maintain high standards of honesty in providing to the best interest of patients, the medical professionals and to all those connected for which the company is being consistently awarded or recognized for its ultimate performance as the enterprise, the administration, the working culture, contribution to the society and the patient support.  

 

Genentech has over 10,000 employees under the Chairmanship of Arthur D. Levinson, who is also the CEO of the company. Hoffmann-La Riche, the multinational Pharmaceutical group from Switzerland currently owns the majority of shares in Genentech Inc.

 

The major world renowned products of Genentech include:

Bio-Oncology: Avastin, Herceptin, Rituxan, Tarceva

Immunology: Raptiva, Rituxan, Xolair

Tissue Growth & Repair: Activase, Cathflo, Activase

Thrombolytic Agent: Lucentis

And so on.